ALT Altimmune Inc

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 and will provide a business update.

Altimmune management will host a conference call at 8:30 am E.T. on August 8 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at .

Participants who would like to join the call may register to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit .

Follow @Altimmune, Inc. on

Follow @AltimmuneInc on

Company Contact:

Vipin Garg

President and Chief Executive Officer

Phone: 240-654-1450

Investor Contacts:

Lee Roth

Burns McClellan

Phone: 646-382-3403

Julia Weilman

Burns McClellan

Phone: 646-732-4443

Media Contact:

Danielle Cantey

Inizio Evoke, Biotech

Phone: 619-826-4657



EN
01/08/2024

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide...

Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected in Q2 2025 End-of-Phase 2 Meeting for the obesity program with U.S. Food and Drug Administration (FDA) has been scheduled for early November 2024 Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning in Q4 2024 GAITHERSBURG, Md., Sept. 30, 2024 ...

4m 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Co...

CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Altimmune, Inc. (Nasdaq:ALT), please note that the reduction of visceral adipose tissue (VAT) at Week 48 has been corrected from 25.6% to 28.3% and the reduction of subcutaneous adipose tissue has been corrected from 20.1% to 19.5%. The revised release follows: Lean Loss Ratio of only 21.9%, representing clas...

September 10, 2024 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub...

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over the age of 60, a population at risk for frailty-related falls and fractures Visceral adipose tissue (VAT), a risk factor for cardiovascular disease, reduced by 25.6% at Week 48 GAITHERSBURG, Md., Sept. 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today...

September 10, 2024 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at ...

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid, Spain. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual recep...

September 3, 2024 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Second Quarter 2024 Financial Results and Provides...

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH) Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH with topline data expected in Q1 2025 Cash, cash equivalents and short-term investments of $164.9 million on June 30, 2024 Webcast to be held today, August 8, 2024, at 8:30 am ET GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: A...

August 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch